Cardinal Health

Overview

Cardinal Health (NYSE: CAH) is the third-largest U.S. pharmaceutical distributor by revenue at $222.6 billion in fiscal 2025, behind McKesson ($359.1B) and Cencora ($321.3B). While distribution dominates the top line, Cardinal has been aggressively building a pharma services ecosystem that extends well beyond its traditional wholesale identity. Through $7.2 billion in acquisitions between March 2024 and November 2025 — spanning oncology, urology, gastroenterology, and diabetes supply management — Cardinal has assembled a multi-specialty services platform. (Source: raw/cardinal-health-pharma-services.md)

Cardinal’s services footprint spans five distinct domains: Sonexus Access and Patient Support (hub/patient access), Nuclear and Precision Health Solutions (nation’s largest radiopharmacy network), at-Home Solutions (direct-to-patient medical supply delivery via Edgepark + ADS), specialty MSO platforms (The Specialty Alliance and Navista oncology alliance, ~3,000 providers across 32 states), and BioPharma Solutions (3PL, consulting, real-world evidence). The services-adjacent “Other” segment generated $5.4B in FY2025 revenue growing at 19% annually with 9.6% margins — notably higher than the Pharma segment’s 1.1% margin. BioPharma Solutions is projecting 30%+ revenue growth in FY2026.

Services & Capabilities

Sonexus Access and Patient Support (Hub Services)

Sonexus is Cardinal’s hub services and patient access platform operating under the BioPharma Solutions umbrella, led by Josh Marsh (VP/GM). Serves 250,000+ patients annually across oncology, rheumatology, and rare disease. Core capabilities:

• Benefits verification & prior authorization — AI/ML-powered automation
• Financial assistance coordination — copay programs, free drug, foundation support navigation
• Non-commercial specialty pharmacy — dispensing and clinical management for restricted-distribution products
• Clinical support — oncology-certified nursing teams for patient education and adherence
• AI-powered patient engagement — 24/7 chatbot, NLP for socioeconomic risk identification
• Data & analytics — behavioral pattern identification, manufacturer reporting dashboards

Flexible service models — a defining differentiator. Sonexus offers three engagement models (fully outsourced, hybrid, fully insourced with tech/data support), embracing the manufacturer insourcing trend rather than fighting it. Recently transitioned “one of the largest single-brand hubs in the industry” for a high-volume multi-indication biologic — a reference case for hybrid transitions. (Source: Drug Channels)

Sonexus competes against McKesson’s CoverMyMeds/Access for More Patients, Cencora’s legacy Lash Group (now classified non-core), and independents like Eversana and IQVIA. Cardinal’s competitive advantage is integration — a manufacturer using Sonexus can access hub, limited distribution, 3PL, and GPO services on the same platform.

Nuclear and Precision Health Solutions

Cardinal operates the largest radiopharmacy network in the United States — nearly 160 nuclear pharmacy locations, 27 cyclotrons supporting PET manufacturing from 90+ locations, reaching 85%+ of U.S. hospitals within 3 hours. Largest employer of nuclear pharmacists globally.

Metric	Value
FY2025 Revenue	$1.58B
FY2025 Growth	15% YoY
Locations	~160
PET Cyclotrons	27
Theranostics Growth (Q1 FY2026)	30%+
PET Expansion Investment	$150M over 3 years, 11 markets

Neither McKesson nor Cencora operates anything comparable. High barriers to entry (NRC licensing, cyclotron capital, time-sensitive logistics for short-half-life radiopharmaceuticals) and tailwinds from the growing radiopharmaceutical pipeline (Novartis Pluvicto, emerging radioligand therapies). Holds contract manufacturing rights for Xofigo (Bayer) and North American rights for Lymphoseek.

at-Home Solutions

Direct-to-patient medical supply delivery including the Edgepark brand and Advanced Diabetes Supply Group (ADS, acquired April 2025 for $1.1B).

Metric	Value
FY2025 Revenue	$3.48B
FY2025 Growth	21% YoY
ADS Patients Served	~500,000

ADS’s ContinuCare Pathway — allowing pharmacies to offload complex Medicare Part B diabetes supply management — has tripled in size since acquisition. Publix enrolled its entire ~1,400 pharmacy network. Cardinal plans to expand ContinuCare beyond diabetes into urology and ostomy. Benefits from aging population (82M Americans 65+ by 2050), hospital-to-home migration, and CMS reimbursement shifts.

BioPharma Solutions (3PL, Consulting, RWE)

Umbrella for manufacturer-facing services beyond Sonexus:

• 3PL/CHPS (La Vergne, TN): Temperature-controlled logistics and custom packaging for specialty/biologic therapies
• Regulatory & clinical consulting: FDA approval support, REMS programs, post-market surveillance
• Real-world data & evidence: Claims and dispensing data across distribution/pharmacy network
• Practice management consulting: Operational/financial advisory for independent specialty practices via MSO platforms
• Specialty Networks (multi-specialty GPOs): Acquired March 2024 for $1.2B

MSO Platforms (Navista + The Specialty Alliance)

Cardinal has assembled a multi-specialty MSO covering ~3,000 providers across 32 states:

• Navista: Oncology practice alliance (50+ sites, 10 states). Expanded via ION acquisition ($1.1B, Dec 2024)
• The Specialty Alliance: Multi-specialty MSO covering urology, GI, rheumatology. Built through Specialty Networks ($1.2B), GI Alliance ($2.8B for 73% stake — 900+ physicians, 345 locations), Urology America ($0.4B), Solaris Health ($1.9B — ~750 urology providers)

OptiFreight Logistics

$324M FY2025 revenue (+18% YoY). Supply chain optimization and freight management.

Competitive Position

Big 3 Services Comparison

Capability	Cardinal	McKesson	Cencora
Hub/Patient Access	Sonexus (mid-tier, flexible models)	CoverMyMeds ($5.2B RxTS, 19.2% margin)	Lash Group (classified non-core; $249.5M impairment)
Nuclear Pharmacy	Market leader (~160 locations)	Minimal	Minimal
At-Home/DTP	Edgepark + ADS ($3.5B)	Limited	Minimal
Oncology MSO	Navista (50+ sites)	US Oncology (~1,500 physicians)	OneOncology, RCA
Multi-Specialty MSO	Specialty Alliance (~3,000 providers, 32 states)	PRISM Vision, Core Ventures	RCA (retina)
3PL	CHPS	McKesson 3PL	World Courier, ICS
Technology/Digital	AI patient engagement (limited scale)	CoverMyMeds (dominant PA platform)	Limited post-hub divestiture

Where Cardinal Wins

• Nuclear pharmacy: Genuine competitive moat with no peer equivalent; multi-decade theranostics tailwind
• At-home/DTP: Edgepark + ADS creates differentiated direct-to-patient channel neither rival has replicated at scale
• Manufacturer flexibility: Sonexus’s hybrid/insourced models resonate with the current insourcing trend
• Multi-specialty MSO breadth: Urology, GI, oncology, rheumatology — broader than McKesson’s oncology-heavy US Oncology

Where Cardinal Is Weakest

• Technology scale: McKesson’s CoverMyMeds ($5.2B, 19.2% margin) dwarfs anything Cardinal has built in digital PA/affordability
• Oncology depth: McKesson US Oncology (~1,500 physicians) and Cencora’s OneOncology give rivals deeper community oncology penetration vs. Navista’s 50+ sites
• Hub brand awareness: Sonexus lacks recognition of legacy Lash Group or CoverMyMeds among manufacturer commercial ops teams
• Specialty pharmacy scale: No full-service retail/mail SP comparable to Accredo, CVS Specialty, or AllianceRx

Cencora Opportunity

Cencora’s decision to classify U.S. consulting/hub services as non-core (Q1 FY2026, $249.5M impairment, exploring divestiture) creates a potential opening for Cardinal to capture displaced manufacturer programs. The Lash Group data breach settlement ($40M) further weakens Cencora’s position.

Recent Developments

M&A Spree ($7.2B, Mar 2024–Nov 2025)

Date	Target	Price	Rationale
Mar 2024	Specialty Networks	$1.2B	Multi-specialty GPOs (urology, GI, rheumatology)
Dec 2024	Integrated Oncology Network (ION)	$1.1B	Oncology MSO; integrated into Navista
Jan 2025	GI Alliance (73% stake)	$2.8B	Largest GI MSO; 900+ physicians, 345 locations
Apr 2025	Advanced Diabetes Supply (ADS)	$1.1B	DTP diabetes supplies; at-Home Solutions
May 2025	Urology America (via GIA)	$0.4B	Urology MSO expansion
Nov 2025	Solaris Health	$1.9B	Largest urology MSO; ~750 providers

Cardinal holds a call right to purchase remaining GI Alliance equity beginning 3 years post-close, suggesting full consolidation intent.

Financial Trajectory

• FY2025: $222.6B revenue, $2.8B non-GAAP operating earnings, $8.24 non-GAAP diluted EPS
• FY2026 guidance: $9.30–$9.50 EPS (+13–15%)
• “Other” segment (Nuclear + at-Home + OptiFreight): $5.4B revenue, $516M profit (9.6% margin), 30%+ profit growth
• BioPharma Solutions: 30%+ revenue growth projected FY2026
• Estimated pharma services-adjacent revenue: $7–8B (3–4% of consolidated but disproportionate profit contribution)

CEO Jason Hollar at JPM 2026: “letting us manage as many of the business aspects as we can provide” for specialty physicians — articulating a platform play, not a distribution play.

Client & Partner Ecosystem

• Hub clients: Top 10 pharmaceutical companies via Sonexus/ConnectSource; specialty pharma manufacturers across oncology, rare disease, rheumatology
• Distribution: ~90% of U.S. hospitals, 60K+ pharmacies
• MSO physicians: ~3,000 providers across 32 states (urology, GI, oncology, rheumatology)
• At-home partners: Publix Super Markets (~1,400 pharmacies enrolled in ContinuCare), home health agencies, hospice organizations
• Nuclear clients: 85%+ of U.S. hospitals within 3-hour reach; Bayer (Xofigo manufacturing), Lymphoseek rights
• Generics sourcing: CVS (Red Oak Sourcing JV)

Technology Platform

• Sonexus: Hub services platform — benefits verification, PA automation, financial assistance, patient engagement
• ConnectSource: Patient engagement and insights platform
• InteLogix: Supply chain predictive analytics using AI
• AI-powered patient engagement: 24/7 chatbot, NLP socioeconomic risk identification (within Sonexus)
• Advanced Therapy Connect: Cell/gene therapy logistics coordination
• ContinuCare Pathway (ADS): Pharmacy-to-DTP diabetes supply management platform; expanding to urology/ostomy

Note: Cardinal lacks a scaled digital PA platform equivalent to McKesson’s CoverMyMeds — a significant technology gap.

Therapeutic Focus

• Oncology: Navista MSO, specialty distribution, Sonexus hub programs
• Urology: Specialty Alliance MSO (Solaris Health, Urology America)
• Gastroenterology: GI Alliance (largest GI MSO nationally)
• Rheumatology: Specialty Alliance coverage
• Rare disease: Sonexus non-commercial pharmacy, BioPharma Solutions launch support
• Radiopharmaceuticals/Theranostics: Nuclear pharmacy — PET diagnostics, targeted radiotherapy (prostate cancer focus currently)
• Diabetes: ADS/ContinuCare at-home supply management
• Cell/gene therapy: Advanced Therapy Connect, 3PL cold chain

Target Customers

• Specialty pharma manufacturers: Seeking integrated hub + specialty distribution + 3PL from a single vendor (especially oncology, rare disease, autoimmune launches)
• Mid-size biopharma: Wanting a hub partner willing to support hybrid/insourced models (vs. demanding full outsource)
• Nuclear medicine/theranostics companies: Requiring national radiopharmaceutical compounding, distribution, clinical trial support
• Independent specialty practices: Seeking MSO-level administrative support while retaining clinical independence
• Pharmacies: Looking to offload complex Medicare Part B supply management (ContinuCare)

Sources

• Cardinal Health FY2025 10-K
• Cardinal Health FY2025 Earnings Release
• Cardinal Health JPM 2026
• Cardinal Health Newsroom — Sonexus
• Drug Channels — Hub Flexibility
• Distribution Strategy Group — Q1 FY2026
• Becker’s — Physician Acquisitions
• IntuitionLabs — Wholesaler Concentration
• Cencora Q1 FY2026 Filing
• McKesson FY2025 Results
• Raw source: raw/cardinal-health-pharma-services.md